Combination of gaba agonists and aldose reductase Inhibitors
AssigneePfizer Inc.
InventorBanavara L. Mylari
Life of this patent
Estimating the term…
Abstract
This invention relates to pharmaceutical compositions comprising combinations of a GABA agonist, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug and an ARI, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug, kits containing such combinations and methods of using such combinations to treat mammals, including humans, suffering from diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic retinopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.
Claims27
A method of treating a diabetic complication in a mammal comprising administering to said mammal in need of such treatment
- (a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist;
- and
- (b) an amount of a second compound, said second compound being an aldose reductase inhibitor or a pharmaceutically acceptable salt of said ARI
- wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable vehicle, carrier or diluent.
A method of treating a diabetic complication in a mammal comprising administering to said mammal in need of such treatment a pharmaceutical composition comprising
- (a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist;
- and
- (b) an amount of a second compound, said second compound being an aldose reductase inhibitor or a pharmaceutically acceptable salt of said ARI.
A pharmaceutical composition comprising:
- a. an amount of a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist;
- and
- b. an amount of an ARI or a pharmaceutically acceptable salt of said ARI.
A kit for achieving a therapeutic effect in a mammal comprising:
- a. an amount of a GABA agonist, or a pharmaceutically acceptable salt of said GABA agonist, and a pharmaceutically acceptable vehicle, carrier or diluent in a first unit dosage form;
- b. an amount of an ARI, or a pharmaceutically acceptable salt of said ARI, and a pharmaceutically acceptable vehicle, carrier or diluent in a second unit dosage form;
- and
- c. a container.
A method for treating a mammal in need of therapeutic treatment comprising administering to said mammal
- (a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist;
- and
- (b) an amount of a second compound, said second compound being an ARI or a pharmaceutically acceptable salt of said ARI wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable vehicle, carrier or diluent.
Dependencies are inferred from the claim text.